{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000069","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-06-09T11:30:05+00:00","discovered_at":"2026-06-09T11:35:00.254546+00:00","generated_at":"2026-06-09T11:36:20.558105+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Autolus files UK annual report highlighting AUCATZYL launch, pipeline progress, and EU sales delay","bullets":["AUCATZYL launched in US (Jan 2025) and UK (Jan 2026) for r/r B-ALL; conditional EU approval but no 2026 sales planned.","Obe-cel paediatric r/r B-ALL Phase 1b showed 95% ORR; Phase 2 enrollment expected complete H1 2027.","Obe-cel advanced to Phase 2 pivotal trial (LUMINA) for lupus nephritis; Phase 1 MS trial dosing started Oct 2025.","Manufacturing site Nucleus in Stevenage, UK; Cardinal Health 105 as US distribution partner.","AGM scheduled for June 29, 2026; ADS holders of record May 27, 2026 eligible to vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000069","json":"https://secwatch.observer/filing/0001730463-26-000069.json","markdown":"https://secwatch.observer/filing/0001730463-26-000069.md","text":"https://secwatch.observer/filing/0001730463-26-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/0001730463-26-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/autl-20260605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:36:20.558105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}